tradingkey.logo

Lifecore Biomedical Inc

LFCR
查看详细走势图
8.170USD
+0.130+1.62%
收盘 12/22, 16:00美东报价延迟15分钟
306.10M总市值
亏损市盈率 TTM

Lifecore Biomedical Inc

8.170
+0.130+1.62%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.62%

5天

+3.68%

1月

+6.94%

6月

+17.72%

今年开始到现在

+9.96%

1年

+12.85%

查看详细走势图

TradingKey Lifecore Biomedical Inc股票评分

单位: USD 更新时间: 2025-12-22

操作建议

Lifecore Biomedical Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名69/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价8.75。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Lifecore Biomedical Inc评分

相关信息

行业排名
69 / 158
全市场排名
176 / 4578
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 5 位分析师
买入
评级
8.750
目标均价
+16.51%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Lifecore Biomedical Inc亮点

亮点风险
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
业绩高增长
公司营业收入稳步增长,连续3年增长24.79%
业绩转亏
公司业绩转亏,最新年度亏损美元
估值低估
公司最新PE估值-7.86,处于3年历史低位
机构减仓
最新机构持股28.27M股,环比减少2.63%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值2.60K

Lifecore Biomedical Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Lifecore Biomedical Inc简介

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
公司代码LFCR
公司Lifecore Biomedical Inc
CEOJosephs (Paul)
网址https://www.lifecore.com/

常见问题

Lifecore Biomedical Inc(LFCR)的当前股价是多少?

Lifecore Biomedical Inc(LFCR)的当前股价是 8.170。

Lifecore Biomedical Inc的股票代码是什么?

Lifecore Biomedical Inc的股票代码是LFCR。

Lifecore Biomedical Inc股票的52周最高点是多少?

Lifecore Biomedical Inc股票的52周最高点是8.850。

Lifecore Biomedical Inc股票的52周最低点是多少?

Lifecore Biomedical Inc股票的52周最低点是4.760。

Lifecore Biomedical Inc的市值是多少?

Lifecore Biomedical Inc的市值是306.10M。

Lifecore Biomedical Inc的净利润是多少?

Lifecore Biomedical Inc的净利润为-44.36M。

现在Lifecore Biomedical Inc(LFCR)的股票是买入、持有还是卖出?

根据分析师评级,Lifecore Biomedical Inc(LFCR)的总体评级为买入,目标价格为8.750。

Lifecore Biomedical Inc(LFCR)股票的每股收益(EPS TTM)是多少

Lifecore Biomedical Inc(LFCR)股票的每股收益(EPS TTM)是-1.040。
KeyAI